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ABSTRACT
Background: Elicitation can be used to characterize structural uncertainty
within a decision analytic model. This allows the value of acquiring further
evidence to resolve these uncertainties to be established.
Aim: This article demonstrated the use of expert elicitation for this
purpose and also compared the elicited results with the results from
alternative assumptions previously used to characterize the uncertainties.
Materials and Methods: Distributions for two unknown parameters were
elicited. These were used within a model developed to assess the cost-
effectiveness of inﬂiximab and etanercept for the treatment of active
psoriatic arthritis (PsA), compared with palliative care. The experts’ dis-
tributions were synthesized using two approaches: linear pooling and
random effects meta-analysis. Weighting of experts is also explored.
Results: The four methods produce broadly similar results, and in each,
the choice of optimum strategy is between etanercept and palliative care
(incremental cost-effective ratio for etanercept is between £29,021 and
£39,259 per costs and quality adjusted life years). Decision uncertainty, at
a £30,000 threshold, is high in all of the synthesis models thus generating
high values of further research at between £141 and £634 million. In each
model, the greatest value of further research was for the short-term effec-
tiveness of treatment (£47–£406 million).
Discussion: Although the cost-effectiveness results do not differ substan-
tially between the models using the elicited values and the original sce-
narios, there are some stark contrasts in terms of the values of further
research generated.
Conclusion: Elicitation offers a feasible method to generate evidence for
the missing information but there are a number of key issues for which
further research is required.
Keywords: cost-effectiveness, decision analysis, elicitation, uncertainty.
Introduction
There is uncertainty in any health technology assessment (HTA)
because we can never predict for certain what the costs and
outcomes associated with particular treatments will be. The char-
acterization of uncertainty is critical in cost-effectiveness analy-
sis, particularly when the decision-maker must consider whether
additional evidence is needed [1].
The sources of uncertainty apparent in cost-effectiveness
studies, have previously been deﬁned as parameter, methodologi-
cal, and structural [2]. Parameter and methodological uncertain-
ties have received signiﬁcant attention within HTA, and as a
consequence, methods for dealing with these uncertainties are
well rehearsed [3,4]. Structural has received relatively little atten-
tion and includes the different types of simpliﬁcations and scien-
tiﬁc judgments that have to be made when constructing and
interpreting a cost-effectiveness analysis of any sort [5]. Often,
there will be a range of plausible or credible assumptions that can
be made. It is important to characterize the uncertainty within
and between these alterative assumptions.
To provide quantitative estimates of the scale of the structural
uncertainties, in relation to other model uncertainties and/or
inform the question of what further evidence would be needed to
resolve these uncertainties, requires parameterization of the
sources of structural uncertainty directly within the model [6].
Often, the use of equal weights for alternative structural assump-
tions is not credible and there is no evidence from which to
generate unequal weights [7]. In these circumstances, subjective
priors for these new model parameters can be elicited from
experts. It is then possible to conduct expected value of informa-
tion analysis (EVI) and establish the value of acquiring further
evidence to resolve these uncertainties [8].
An elicitation method is intended to link an expert’s under-
lying beliefs to an expression of these in a statistical form [9].
Elicitation techniques have received a lot of focus in Bayesian
statistics because of the need to formulate a prior distribution
[10]. However, expert elicitation may also be required when data
is either absent, insufﬁcient, or biased.
Elicitation methods have had a limited impact in decision
analysis with very few practical applications [11–13]. The appli-
cations conducted to date have typically elicited single values
such as the mean, thereby ignoring any uncertainty in the elicited
beliefs.
The purpose of this article is to demonstrate how elicitation
methods can be used to parameterize structural uncertainties
within a case study model with multiple uncertainties. In addi-
tion, a comparison of alternative methods to synthesize elicited
distributions from multiple experts is undertaken. The article
ﬁrst describes the structural uncertainties apparent in the case
study model and then goes onto describe the elicitation methods
that were used to generate prior distributions. The results,
including those generated using the alternative synthesis
methods, are then discussed and compared.
An Example Model
A probabilistic decision analytic model was previously developed
to assess the cost-effectiveness of new biologic drugs (anti-tumor
necrosis factor [anti-TNF] for the treatment of active psoriatic
arthritis (PsA), speciﬁcally inﬂiximab and etanercept compared
with palliative care [14,15]. This assessment was commissioned
by the National Collaborating Centre for Health Technology
Assessment (NCCHTA) on behalf of the National Institute for
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Health and Clinical Excellence (NICE). The model used a health
care (UK National Health Service) perspective and assumed a
10-year time horizon.
Outcomes of treatment were expressed as both initial
response at 3 months posttreatment (the Psoriatic Arthritis
Response Criteria [PsARC]) and disease activity (Health Assess-
ment Questionnaire [HAQ]). HAQ scores range from 0 to 3 with
3 representing the most severe state. Costs and quality adjusted
life years (QALYs) for the comparators were generated using two
regression models mapping HAQ scores onto utilities and costs
[14,15]. Further details of the model can be found elsewhere
[14,15].
Without treatment, patients symptoms worsen over time (an
increase in HAQ score of +0.016 HAQ every 3 months) [14,15]
in line with natural history progression. Patients who receive and
respond to etanercept or inﬂiximab, using PsARC [14,15], expe-
rience an initial (3-month) drop in HAQ score (referred to as
initial gain) as well as a possible halt in disease progression after
the initial response. Mean baseline HAQ is ﬁxed at 1.16 and is
taken from a meta-analysis of three trials conducted in Winbugs
[14,15]. The initial HAQ gain, again estimated from trial data, is
-0.579 (standard deviation [SD] = 0.0937) for inﬂiximab and
-0.632 (SD = 0.089) for etanercept [14,15].
Limited data on the longer-term effect of etanercept and
inﬂiximab, beyond the initial gain, meant that a number of
assumptions, regarding structural uncertainties, were made in the
original model. These are:
• Disease progression following a response to etanercept or
inﬂiximab is not known. In the original model, the assump-
tion is that beyond the initial HAQ gain, disease progres-
sion will stop (see Fig. 1) and no alternative scenarios were
speciﬁed.
• The rate of disease progression following withdrawal from
treatment (given an initial gain) is not known. Clinical
opinion suggests that there will be some kind of rebound
(worsening of HAQ score for the 3 months following with-
drawal), but the degree of rebound is unknown. In the
original model, two rebound scenarios were therefore con-
sidered (see Fig. 1):
1. When patients fail therapy (after initially responding),
their HAQ score deteriorates by the same amount by
which it improved when patients initially responded to
therapy (rebound equal to gain in Fig. 1). It then
returns to the natural history trajectory.
2. When patients fail therapy, their HAQ score returns to
the level and subsequent trajectory it would have been
had they not initially responded to therapy (rebound
to natural history in Fig. 1).
The two rebound scenarios for progression following relapse
produce two different estimates of the cost-effectiveness of etan-
ercept and inﬂiximab (incremental cost-effective ratios [ICERs]
of £26,361 and £30,628 for etanercept) (see Table 4). This
increase in the ICER may be sufﬁcient to change the adoption
decision, if the threshold is greater than £26,361 but less than
£30,628.
Decision uncertainty also changes according to which
assumption is made about the rebound. The probability that
etanercept is cost-effective, at a £30,000 threshold is 0.693 in the
scenario where rebound is equal to gain and 0.446 in the scenario
where rebound is equal to natural history. EVI analysis was also
conducted on the decision and model parameters using simulated
costs and outcomes generated by the model [1]. The probability
of making the wrong decision and the costs of making the wrong
decision (net beneﬁt forgone, calculated as costs minus QALYs
multiplied by the threshold [16]) determines the expected cost of
uncertainty. These costs can be interpreted as the EVI, because
having information can eliminate the possibility, and hence costs,
of making the wrong decision [1]. Per patient EVI is scaled up to
represent the value of research for a population, given a particu-
lar lifetime of the technology [1], in this case 10 years. The
relevant population size for the PsA model is 12,000 new patients
per annum in England and Wales [14].
Total EVI, at a threshold of £30,000, is £23 million when
rebound is equal to gain and £34 million when rebound is equal
to natural history. EVI on model parameters was conducted for
the scenario specifying rebound equal to gain. This suggested
that further research should focus primarily on obtaining more
information about the short-term effectiveness of treatments
(£25 million) and the quality of life for PsA patients (£11
million). As the two scenarios for rebound following relapse were
run as separate scenarios, it is not possible to estimate the EVI for
this structural uncertainty.
The two structural uncertainties are essentially model param-
eters on which we have no prior information. An elicitation
exercise was therefore designed to derive distributions to explic-
itly characterize both of the PsA model uncertainties. The
purpose of explicitly characterizing the uncertainties was to
allow the maximum value of further research on these uncertain-
ties to be estimated and compared with the value generated for
other groups of model parameters through the use of EVI analy-
sis. There are also reasons to believe that the two uncertain
parameters may be related, that is that the degree of rebound
3
H
A
Q
2
1
0 3……. Time (months)
Initial 
gain
Rebound 
equal to gain
Rebound to natural history
Disease
progression 
following a 
response = 0
Figure 1 Disease progression following
treatment failure. HAQ, Health Assessment
Questionnaire.
558 Bojke et al.
following relapse is conditional upon the extent of gain when
responding, therefore the conditional relationship between
parameters must be captured when eliciting judgments from
experts.
The Elicitation
An elicitation exercise was designed to gather experts judgments
on the two structural uncertainties described above. The elicita-
tion exercise took around 2 weeks to design and a further 2
weeks to conduct the elicitation and synthesize the distributions.
To capture uncertainty both within and between experts,
distributions were elicited from multiple experts individually,
rather than from a group of experts simultaneously. The follow-
ing sections describe the study sample, elicitation format, the
elicitation questions, and the questionnaire responses.
Study Sample
Questionnaires were sent to 16 experts, chosen on the basis of
advice from a clinical collaborator. All experts were senior rheu-
matologists (consultant or above). All were within a reasonably
close geographical location to the authors as interviews were
conducted face-to-face. The experts all had considerable experi-
ence of working with PsA and routinely used anti-TNFs to treat
their patients. All experts had some experience of using the HAQ
to assess disease progression, although some used it more rou-
tinely than others.
Eleven experts did not respond to the request to complete the
questionnaire. The reason for this is unclear, although it may
have been due to the technical burden of the questionnaire.
Follow-up correspondence was undertaken on numerous occa-
sions; however, this did not result in further responses. Complete
questionnaires were available from ﬁve experts.
Format of the Elicitation
A mathematical approach to elicitation was used [17]. Using this
approach, beliefs were elicited from multiple experts individually,
followed by appropriate synthesis. To facilitate this, a
spreadsheet-based (Excel) exercise was designed to elicit esti-
mates of 3-month disease progression while responding to treat-
ment and for the 3-months following a relapse. The elicitation
exercise was also designed to incorporate any correlation
between these two parameters. To capture any relationship
between parameters, responses for questions were conditional
upon responses to previous questions. This method is an appro-
priate way to incorporate conditional dependence suggested by
Garthwaite, 2005 [9].
In accordance with good elicitation practice, background to
the elicitation was presented at the start of the exercise along
with a guide to completion [18]. Experts were told the rationale
for the elicitation exercise and reminded of the HAQ scoring
method and expected natural history progression (progression
without treatment). Experts were presented with an illustration
of the trajectory of disease progression without treatment and
change in HAQ score. Experts were also reminded not to be too
over conﬁdent with their beliefs.
The histogram approach [19] was used to represent beliefs.
For each question, a discrete numerical scale was predeﬁned and
experts were asked to place 20 crosses on a frequency chart,
representing their beliefs about the distribution of a particular
quantity. Each cross represents 5% of the distribution.
Elicitation Questions
Experts were ﬁrst presented with a series of example questions,
relating to the temperature in UK cities conditional upon the
temperature in other UK cities. These example questions were
intended to familiarize the expert with the format of the elicita-
tion. Once the expert had completed these example questions,
they were asked to start the actual elicitation questions. The three
questions were repeated for both etanercept and inﬂiximab.
Question 1: Initial HAQ gain. Experts were asked to provide an
estimate of the seed questions (HAQ gain) following treatment,
which served to calibrate experts (see Calibration section below)
[18]. Experts were asked for their estimates of HAQ score fol-
lowing treatment (3-month response) and were required to place
20 crosses on a grid ranging from 0 to +3.
Question 2: Rate of progression while still responding to treat-
ment. Experts were asked to provide an estimate of disease
progression for patients who have responded to treatment, given
particular intervals for this initial HAQ gain. These initial HAQ
changes were taken as the 0–25, 25–50, 50–75, and 75–100th
percentiles from the original Winbugs output of HAQ scores [14]
for etanercept and inﬂiximab separately. Experts were reminded
prior to answering these questions that the 3-month natural
history rate of progression (progression without treatment) is
+0.016.
Question 3: Rate of progression after treatment failure. Experts
were asked to provide an estimate of disease progression for the
3 months following a treatment failure (after an initial response);
this was termed the “rebound.” Experts were asked to specify a
rebound conditional on particular ranges of progression while
responding (0–25, 25–50, 50–75 and 75–100th percentiles).
These ranges were generated by sampling 10,000 times from the
responses to question 2, given the likelihood of observing a
particular conditional HAQ gain (question 1).
At the end of question 3, experts were given the opportunity
to view a summary of their responses, presented as probability
distributions. Experts were then given the opportunity to provide
feedback on the questionnaire and/or start the questionnaire
again.
Questionnaire Responses
Table 1 shows the mean responses for each of the ﬁve experts
with SD in brackets. These have been estimated directly from the
experts’ elicited histograms. Table 1 also shows mean and SD
from the Winbugs output for the seed questions. Correlation
coefﬁcients showed that the correlation between elicited param-
eters is not signiﬁcant (correlation coefﬁcients close to zero).
Looking at individual responses, experts 1 and 4 provide
estimates of HAQ gain that are inconsistent with the seed values
(see calibration of experts beliefs), they state that inﬂiximab is
more effective (larger initial gain) than etanercept when in fact
etanercept is more effective than inﬂiximab. Experts 2, 3, and 5
believe that the HAQ gain is the same for both treatments.
Overall, experts believe the effect of inﬂiximab and etanercept is
greater than the trial data suggests. The mean elicited HAQ gain
was -0.894 for etanercept and -0.952 for inﬂiximab. This is
somewhat higher than the actual mean gain of -0.632 and
-0.579 for the two drugs and also suggests a different ordering in
terms of effectiveness.
Comparing the elicited values of the two unknown param-
eters to those used in the original model suggests that there may
have been an over-estimation of the effectiveness of both drugs.
The original model assumed that patients’ HAQ scores did not
change following the initial gain after a treatment response (pro-
gression while responding = 0). Table 1 shows that experts dis-
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agree with this assumption. Values ranged from 0.007–0.053 for
etanercept and 0.009–0.057 for inﬂiximab. The mean elicited
progression is 0.026 for etanercept and 0.027 for inﬂiximab
which is somewhat lower than natural history progression
(0.065) but much higher than 0. The conclusion is therefore that,
the results of this elicitation exercise show that patients’ disease
progression on inﬂiximab is slightly faster than etanercept.
It would seem reasonable to assume that progression follow-
ing relapse would be faster compared with progression while
responding; however, there is one illogical response in Table 1
where progression after relapse is actually slower than progres-
sion while responding. This response was given by Expert 2 in
relation to inﬂiximab. Overall, experts believed that progression
would be faster following a relapse, with values ranging from
0.06 to 0.106 for etanercept and from 0.036 to 0.053 for inﬂix-
imab. The mean elicited progression was 0.073 for etanercept
and 0.044 for inﬂiximab. This is higher than the natural history
progression suggesting that relapse changes the course of the
disease and that the effects are greater than just the initial
increase in HAQ score.
There is considerable heterogeneity between experts’ beliefs
for the unknown parameters. The exact reason for this is difﬁcult
to determine, but possible reasons are: clinical knowledge, clini-
cal experience (types of patients seen and/or drugs used), access
to promotional materials by industry marketers, interpretation
and understanding of elicitation questions and true underlying
heterogeneity about the treatment effect. Unfortunately it is not
possible, with ﬁve experts, to incorporate these factors, as cova-
riates, into a model. To do this would require many more experts
to estimate with any degree of precision.
Calibration of Expert’s Beliefs
The purpose of calibration is to derive a relative weighting index
for each expert based on their responses to seed questions [17].
These weights are then used to adjust the estimates of unknown
parameters, so that the expert with the highest weight contrib-
utes the most to the pooled estimate and the expert with the
lowest weight contributes the least. The seed questions used to
weight experts’ beliefs in this exercise, were the responses to
initial HAQ gain for etanercept and inﬂiximab. Weights are
derived separately for etanercept and inﬂiximab.
Method Used to Calibrate
A number of methods exist to generate weights for individual
experts. Perhaps the most well known of these is the classical
model [17]. In the classical model, weights are determined by the
normalized product of an expert’s calibration score and overall
information score [17]. The calibration score is the probability
that the difference between the experts score and the realization
could have occurred by chance [20]. The information score is
then the degree to which the expert concentrates his or her
probability mass on a small region or the width of the uncer-
tainty band [20]. More informative distributions are derived by
choosing quantiles which are closer together (less uncertain);
whereas, less informative distributions result when the quantiles
are further apart (more uncertain).
The limitations of the classical model lie in the fact that when
generating calibration scores using the likelihood, the seed(s) are
assumed to be known with certainty, and are entered as a single
realization. However, this is an unlikely assumption and often,
this realization may be one of an inﬁnite number of realizations.
In addition, experts are rewarded for providing more informative
distributions, as compared with a uniform distribution for
example. Experts expressing less diffuse distributions, however,
may not be more knowledgeable and thus provide better esti-
mates of unknown parameters.
An alternative method that utilizes the entire distribution
elicited from experts and the entire distribution from the seeds to
calibrate experts is used here [6]. To generate weights for each
expert, the distributions for each seed were sampled (shown in
Table 2) along with the relevant empiric distributions elicited
from each experts’ histogram. The distance between expert’s
beliefs and the relevant seed question was then calculated. The
expert that minimized this distance was assigned a point
(accounting for ties). This process was repeated for 10,000 itera-
tions and weights were calculated as the sum of all points for
each expert over the total number of samples. This way, the sum
of the weights over the experts returns one. The expert with the
highest number of points was classed as the most accurate and
thus received the highest weight score.
This method recognizes that the seed is not actually known
with certainty, thus we cannot simply use a single value for the
seed to generate weights for experts. In addition, this method
does not impose any penalty for experts providing more diffuse
distributions, it is the distribution of known parameters that
determine if an expert is assigned a high weight or not.
Calibration Results
Table 2 shows the calibration weights generated for each expert
for etanercept and inﬂiximab. Based on responses to the seed
Table 1 Responses to elicitation questionnaire
Expert
HAQ gain Progression while responding Progression on relapse
E I E I E I
1 -0.64 (0.15) -0.83 (0.14) 0.016 (0.008) 0.01 (0.009) 0.069 (0.009) 0.047 (0.032)
2 -0.78 (0.08) -0.78 (0.08) 0.053 (0.046) 0.057 (0.046) 0.106 (0.037) 0.053 (0.037)
3 -0.87 (0.16) -0.88 (0.16) 0.04 (0.008) 0.036 (0.009) 0.064 (0.006) 0.049 (0.028)
4 -1.17 (0.13) -1.26 (0.13) 0.007 (0.004) 0.009 (0.006) 0.065 (0.009) 0.036 (0.038)
5 -1.01 (0.20) -1.01 (0.20) 0.014 (0.010) 0.014 (0.011) 0.06 0.06
Seed values -0.632 (0.06) -0.579 (0.09) — — — —
HAQ, Health Assessment Questionnaire; E, Etanercept; I, Inﬁiximab.
Table 2 Calibration results
Expert
number
Weight—
etanercept
Weight—
inﬂiximab
1 0.7032 0.0728
2 0.2042 0.6016
3 0.0703 0.3099
4 0.0022 0.0005
5 0.0202 0.0153
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questions, and relative to each other, Expert 1 is better at pre-
dicting the value for etanercept but Expert 2 is better at predict-
ing for inﬂiximab. Expert 3 is relatively much better at predicting
the value for inﬂiximab compared with etanercept (weight is 0.31
compared with 0.07). This may reﬂect experts’ experience with
speciﬁc drugs. Experts 4 and 5 are poor at predicting values for
both etanercept and inﬂiximab and, as such, are assigned rela-
tively small weights.
Synthesis of Experts’ Judgments
In order to utilize the experts judgments within the decision
model, each of the ﬁve sets of histograms had to be synthesized.
Linear pooling is the method most commonly applied in expert
synthesis [17]. It may also be possible to use methods tradition-
ally used to synthesize trial data when synthesizing experts’ prior
distributions, namely meta-analysis techniques. Thus, two alter-
native methods to synthesize distributions from the multiple
experts were applied: linear pooling and a random effects model.
The details of these two methods are described below.
Linear Pooling
In linear pooling, experts’ probabilities or weights are aggregated
using simple linear combinations. If p(q) is the probability dis-
tribution for unknown parameter q, experts’ probabilities or
weights are aggregated using simple linear combination, p(q) =
Si wi * pi(q) where wi is expert i’s weight.
This method is akin to generating a “super” distribution by
pooling the ﬁve experts’ beliefs. From this, we can generate an
arithmetic mean and associated uncertainty [21]. The linear
pooling method considers each expert’s distributions as separate
priors with no relationship between experts’ distributions
assumed.
Linear pooling was ﬁrst carried out using equal weights for
experts and then using unequal weights estimated by calibrating
experts’ opinions (see above).
Random Effects Meta-analysis
Methods traditionally used to synthesize trial data represent
potentially plausible methods to synthesize experts’ priors. Typi-
cally the mean of a random effects meta-analysis is used as
the estimate of effect [22]. This assumes that there is an exclusive
estimate of effect that can be estimated and that the mean, and
estimate of uncertainty, constitutes our sum knowledge of this
effect [22]. What we actually want is an estimate for a randomly
drawn and representative expert. To do this we use the predictive
distribution from the random effects model, which can be esti-
mated as the e + 1 expert [22], where e is the ﬁve experts for
which responses are available.
A Bayesian random effects model was speciﬁed, where the
decision-maker (in this case the analyst) speciﬁes an uninforma-
tive prior for the unknown parameters, and experts beliefs
(assumed to be normally distributed) are used as trial data which
are used to update this prior and produce posterior distributions.
Random effect meta-analysis was carried out using equal and
unequal weights for experts. To allow convergence, 70,000 itera-
tions were run for both models. From this, the ﬁrst 20,000 “burn
in” iterations are disregarded.
Pooled Estimates of the Unknown Parameters
The two synthesis methods (described above) were used to gen-
erate estimates for the two unknown parameters. In addition,
weighting was applied using the weights presented in Table 3.
The synthesis results for the unknown parameters, with (W_WT)
and without (W/O_WT) weighting are shown below in Table 3.
Table 3 shows that the estimates of the two unknown param-
eters for etanercept and inﬂiximab are sensitive to the synthesis
method used. The unweighted linear pooling model predicts the
fastest disease progression while responding for etanercept
(0.024), and the weighted linear pooling model the fastest disease
progression while responding on inﬂiximab (0.047). The
weighted random effects model gives the fastest disease progres-
sion after relapse on etanercept (0.0851) and inﬂiximab
(0.0853).
There are some noticeable differences between the
unweighted and weighted models. In particular, inﬂiximab is
associated with a much faster disease progression in the weighted
linear pooling model compared with the unweighted linear
pooling model (particularly while responding). This is because a
high weight is attached to Expert 2 (0.601) who gives a high rate
progression for inﬂiximab while responding (0.057) and after
relapse (0.053).
Implications for the Adoption Decision
Estimates of the unknown parameters, derived for the two
methods (with and without weighting) of synthesis, were applied
to the PsA model. The cost-effectiveness results for all are shown
in Table 4 compared with the original two scenarios: rebound
equal to gain (scenario 1) and rebound equal to natural history
(scenario 2).
Results from the two random effects models are similar to the
two original scenarios (ICERs for etanercept: scenario 1 =
£26,361, scenario 2 = £30,628, random effects unweighted =
£29,021, random effects weighted = £30,132). These ICERs are
on the border of what is likely to be considered cost-effective
[23]. Either etanercept or palliative may represent the optimum
strategy, and decision-makers are likely to consider other factors,
such as patient preferences, when considering which strategy to
adopt.
The linear pooling models are somewhat different with ICERs
for etanercept of £37,749 and £39,259 for linear pooling with
and without weighting. This suggests that etanercept is unlikely
to be cost-effective at acceptable values for the threshold [23]. It
is therefore likely that palliative care would be considered the
optimum strategy.
Table 3 Results from synthesis of known and unknown parameters mean (standard deviation)
Progression while responding Progression after relapse
Etanercept Inﬂiximab Etanercept Inﬂiximab
Linear pooling (W/O_WT) 0.024 (0.009) 0.022 (0.008) 0.054 (0.010) 0.067 (0.007)
Linear pooling (W_WT) 0.023 (0.013) 0.047 (0.028) 0.040 (0.010) 0.076 (0.018)
Random effect (W/O_WT) 0.0182 (0.0153) 0.0180 (0.0155) 0.0730 (0.022) 0.0714 (0.0238)
Random effect (W_WT) 0.0191 (0.0112) 0.0193 (0.011) 0.0851 (0.0163) 0.0853 (0.0146)
W/O_WT, without weighting; W_WT, with weighting.
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Weighting experts in the linear pooling model produces much
lower QALYs for inﬂiximab than the unweighted model; this is
because of the faster disease progression when weighting experts’
estimates (Table 3). A high weight is attached to Expert 2 (0.601)
who gives a high rate of progression for inﬂiximab while
responding (0.057) and after relapse (0.053). Inﬂiximab is thus
dominated in the weighted linear pooling model. The weighted
random effects model produced similar results to the unweighted
model, and as such, the ICER for etanercept is similar.
In the unweighted linear pooling model, the probability that
the optimum strategy, palliative care, is cost-effective at a
£30,000 threshold is 0.768. In the weighted linear pooling
model, this is slightly less at 0.7. Decision uncertainty in the
unweighted random effects model reﬂects the fact that the ICER
for etanercept is on the border of what would be considered
cost-effective [23], at a threshold of £30,000 per QALY. The
probability that etanercept is cost-effective is 0.479 and the prob-
ability that palliative care is cost-effective is 0.437. Decision
uncertainty is lower in the weighted model because, at a £30,000
threshold, palliative care would be the optimum strategy (prob-
ability = 0.48).
In the original scenario 1, the probability that etanercept is
cost-effective is 0.693. This falls to 0.446 in scenario 2 where
instead palliative care is the optimum strategy (probability of
being cost-effective = 0.554).
Implications for Decision Uncertainty and
Research Recommendations
The large amount of uncertainty in both of the linear pooling
models generates high values of further research at £141 million
and £230 million, at a threshold of £30,000, in the unweighted
and weighted models, respectively. EVI analysis suggests that
many of the parameters (short-term effectiveness, costs, and utili-
ties) were associated with high values of further research (£0.79
to £147 million); however, the greatest value of further research
was for the short-term effectiveness of treatment at £47 million in
the unweighted model and £148 million in the weighted model.
The unknown parameters were also associated with value at £24
million in the unweighted model and £42 million in the weighted
model. It is likely that further research on these unknown param-
eters would be regarded as cost-effective.
The adoption decision in the unweighted random effects
model is particularly uncertain. Because of this, the value of
further research is very high at £634 million. The value of further
research is lower than the unweighted model at £522 million but
again suggests that further research may be worthwhile. In terms
of the focus for further research, the unweighted random effect
model suggested that the most value is associated with obtaining
more information about the short-term effectiveness of treat-
ments (£406 million) and that, among others, the unknown
parameters are also associated with a high value of further
research (£61 million). The weighted random effect model sug-
gests that further research should again focus on effectiveness of
treatments (£399 million). The maximum value of further
research on the unknown parameters for the weighted model is
£47 million.
These total values of further research are much higher than
the EVI values generated in the original scenarios (£23 million in
scenario 1 and £34 million in scenario 2). This is because in
scenario 1, there is a high probability of etanercept being cost-
effective, which is also the treatment with the highest QALYs.
Although the probability that palliative care is cost-effective is
higher in the unweighted linear pooling model, the consequences,
in terms of forgone QALYs are much more and thus the EVI is
higher. In scenario 2, the EVI results are very different to the
weighted random effects model, which has a similar ICER for
etanercept, because the adoption decision is much less ﬁnely
balanced between etanercept and palliative care.
Discussion
A de novo elicitation task was designed here to generate esti-
mates for two unknown parameters within the psoriatic arthritis
decision model, disease progression while responding to treat-
ment and disease progression on relapse. Although the cost-
effectiveness results do not signiﬁcantly change from those
generated using the original two scenarios, the estimates of the
value of further research differ greatly.
Conducting an elicitation of this type within the timelines of
an ongoing appraisal, however, presents a signiﬁcant challenge
Table 4 Results from alternative scenarios and using alternative synthesis methods with elicited data
Strategy Cost (£) QALY ICER (£) Prob c/e (£30,000)* EVI (£30,000)
Scenario 1 Inﬂiximab 64,274 4.363 ED 0.001 £23 million
Etanercept 44,111 4.514 26,361† 0.693
Palliative care 10,718 3.248 — 0.306
Scenario 2 Inﬂiximab 64,418 4.455 205,345 0 £34 million
Etanercept 44,169 4.356 30,6282 0.446
Palliative care 10,679 3.263 — 0.554
LP-UW Inﬂiximab 64,633 4.129 1,482,404‡ 0.004 £141 million
Etanercept 44,373 4.115 39,25 0.224
Palliative care 10,660 3.256 — 0.768
LP W Inﬂiximab 65,298 3.291 D 0.03 £230 million
Etanercept 44,391 4.153 37,749 0.297
Palliative care 10,708 3.261 — 0.7
RE-UW Inﬂiximab 64,357 4.464 355,181 0.084 £634 million
Etanercept 44,131 4.407 29,021 0.479
Palliative care 10,647 3.254 — 0.437
RE-W Inﬂiximab 64,473 4.419 401,377 0.056 £522 million
Etanercept 44,252 4.369 30,132 0.464
Palliative care 10,744 3.257 — 0.48
*Threshold for cost-effectiveness.
†Compared with palliative care.
‡Compared with etanercept.
LP_UW, linear pooling unweighted; LP_W, linear pooling weighted; RE_UW, random effects unweighted; RE_W, random effect weighted; QALY, quality adjusted life years; ICER, incremental cost
effectiveness ratio; EVI, expected value of information; Prob c/e, Probability that strategy is cost-effective; D, dominated.
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and there are a number of broader issues that require further
consideration: Firstly, there is the issue of which experts to elicit
from. The elicitation literature is unclear who exactly is an
expert. It simply suggests that an expert should be a “substantive
expert in the particular area” [24]. The issue of whether
an expert should possess any particular skills in elicitation is less
clear and will depend on the complexity of the elicitation task.
More competent experts may be required for elicitation of quan-
tities such as population moments or functions of parameters.
Ideally, experts should be representative of all experts for which
the decision problem is relevant, in this case England and Wales,
as the model was originally developed to inform an appraisal for
NICE. The limited geographical area from which the experts
were drawn may impact on the generalizability of the results.
There may also be an issue of responder bias, that is those who
agreed to complete the exercise may differ in some way to those
who did not agree to participate. Even if particular characteris-
tics of sampled and unsampled experts were available and then
compared, it may be that it is unknown (and possibly undeter-
minable) characteristics of experts that determine their willing-
ness to participate.
The second issue is what to do with the elicited distributions,
in particular how to calibrate experts and how to synthesize their
distributions. This article explores the use of calibration to
weight experts’ priors on unknown parameters. This is an
attempt to account for any differences in experts’ suitability to
provide distributions for unknown parameters by assigning dif-
ferential weights in the synthesis.
In the case study exercise, weighting did not have a discern-
able impact on the adoption decision; however, it did inﬂuence
decision uncertainty and as a result, changed the estimates of the
value of further research. For the linear pooling method, weight-
ing increases the decision uncertainty and thus EVI increases
from £141 million to £230 million. In the random effects model,
it had the opposite effect, decreasing decision uncertainty and
thus reducing EVI. Therefore, there is no clear message from this
case study on the impact of calibration.
This issue of whether or not to calibrate is contentious in
elicitation. Calibration may produce more accurate prior distri-
butions for unknown parameters. However, there are a number
of reasons to be cautious about the results of calibration. In
many circumstances, it is necessary to rely on a relatively small
number of known parameters to calibrate. In addition, given
that known parameters are often derived from trial or other
published estimates, it is likely that an expert in the area would
be aware of this information and as such, they may be able to
provide very accurate estimates of known parameters, but this
may not indicate that they are more likely to provide accurate
beliefs for unknown parameters, where literature does not
exist.
Once experts’ distributions on the seed parameters have been
collected, there is also the question of which method should be
used to generate weights. The method used here, and indeed the
classical model described, generates weights using experts’ per-
formances relative to one another. It may be more appropriate to
assign experts an absolute rather than a relative weight with the
decision-maker (or analyst) taking up the remainder of the unas-
signed weighting. These absolute weights could be determined by
developing a scoring system based on experts’ distance from
sampled trial data. For example, a score of one could be assigned
to an expert if their sampled value was within three SD of the
sampled trial data, and a value of two assigned to an expert if
their sampled value was within two SD of the sampled trial data,
and so on. This system is likely to result in somewhat smaller
weights for experts, with the likelihood that some experts may be
assigned a zero weight. The issue then is what prior to assign to
the decision-maker? In the absence of an informative prior, a
vague prior could be assigned to the decision-maker (as with the
random effects model conducted here) such as a 0–1 range for
prior probabilities. The problem with this approach is that it
could produce synthesized priors that are very uncertain;
however, if this reﬂects the current state of knowledge on the
unknown parameters this may generate more accurate estimates
of the value of further research.
In this case study, the ﬁve experts’ beliefs were synthesized in
order for them to be useful inputs into the PsA decision model.
Synthesis was undertaken using both linear pooling and random
effects meta-analysis techniques. There is some variation in the
ICER for etanercept produced from the four synthesis models,
ranging from £29,021 in the unweighted random effects model to
£39,259 in the unweighted linear pooling model. Given the dif-
ferences between the two methods of synthesis it is important to
consider which is the most appropriate method for use in
decision-analytic models and thus ultimately for informing the
decision-making process. Linear pooling considers each expert’s
distributions as separate priors with no relationship between
experts’ distributions assumed. As more priors are gathered the
overall distribution can potentially become wider, thus we don’t
necessarily reduce uncertainty by eliciting beliefs from more
experts. In the random effects synthesis, the estimate of progres-
sion can again vary across experts. Like the linear pooling
method, two sources of variation therefore incorporated,
between expert variation and within expert uncertainty [25]. In
the Bayesian random effects synthesis, the priors are treated like
data, with separate priors (non-informative in this instance)
placed on these. These are then combined to generate posterior
estimates of the unknown parameters. The random effects pre-
dictive model predicts the next expert using information on the
within and between expert variation from the previous ﬁve
experts. The random effects predictive model does not reﬂect the
current state of knowledge on the unknown parameters. This can
only be achieved by using linear pooling to synthesize experts’
priors and thus this method should be used to synthesize experts’
priors on elicited parameters.
Uncertainties are unavoidable in any cost-effectiveness
analysis. It is important to appropriately characterize these
uncertainties, so that we can determine accurate estimates of
cost-effectiveness and the value of conducting further research.
Elicitation offers a feasible method to generate distributions for
these uncertainties. However, conducting an elicitation is a long
and complex task and, unfortunately, many elicitation question-
naires are context speciﬁc which often means a long design
process at the start of any elicitation exercise. Questionnaires
that require us to elicit distributions on more complex model
parameters can also present difﬁculties for experts. There may
well be a trade-off between obtaining information on speciﬁc
model parameters, the complexity of the exercise and cognitive
burden on experts.
Despite the potential time input required for a formal elicita-
tion, the potential for using elicitation in HTA decision models is
considerable. This case study illustrates just one potential use, to
generate missing information on structural uncertainties;
however, there are many other potential uses, including valida-
tion of model assumptions or sources of evidence. Elicitation can
also be used to provide more informative priors on model param-
eters, which can then be combined with other forms of data.
One thing that is apparent from the exercise is that the use of
expert elicitation to characterize issues of uncertainty, poses a
number of challenges and uncertainties, these include the method
of synthesis and the use of weighting. However, it is likely that a
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clearer understanding, of which elicited methods are appropriate
for HTA application, will emerge with further research and
application.
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